Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIHARIKA B METTU

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1447427737
CMS profile
916702
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$144.15

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Notal Vision, Inc. $144.15 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIHARIKA B METTU

NPI 1447427737 · CMS profile ID 916702

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447427737?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447427737?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447427737?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NIHARIKA B METTU, NPI 1447427737, CMS profile ID 916702, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1447427737?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $144.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Notal Vision, Inc. $144.1504/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957139595 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $84.58 2
PY2022 $144.15 1
PY2023 $404.87 2
PY2025 $118.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $412,481.43 29
PY2024 Principal investigator $438,364.30 16
PY2023 Recipient $1,900.00 1
PY2023 Principal investigator $221,978.88 12
PY2022 Recipient $940.00 1
PY2022 Principal investigator $540,890.16 21
PY2021 Principal investigator $466,508.69 60
PY2020 Principal investigator $671,262.43 162
PY2019 Principal investigator $961,160.26 152

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

162 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17.45 12/31/2020 Non-covered Recipient Entity
Duke Clinical Research Inst
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 736736033
Principal investigator 1 AstraZeneca Pharmaceuticals LP $485.65 12/31/2020 Covered Recipient Teaching Hospital
Duke University Hospital
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 736748053
Principal investigator 1 AstraZeneca Pharmaceuticals LP $586.80 12/31/2020 Non-covered Recipient Entity
Duke University
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 736750211
Principal investigator 1 Incyte Corporation $891.00 12/22/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302575
Principal investigator 1 Incyte Corporation $189.90 12/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282367
Principal investigator 1 Incyte Corporation $95.00 12/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292147
Principal investigator 1 Genentech, Inc. $1,250.00 11/24/2020 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
CAPECITABINE AVASTIN PLUS PDL1 MPD3280A OR ACTEMRA TOCILIZUMAB No dispute reported 06/30/2026 743075573
Principal investigator 1 Genentech, Inc. $6,100.00 11/20/2020 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
CAPECITABINE AVASTIN PLUS PDL1 MPD3280A OR ACTEMRA TOCILIZUMAB No dispute reported 06/30/2026 743075561
Principal investigator 1 Incyte Corporation $95.00 11/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292139
Principal investigator 1 Incyte Corporation $2,745.90 10/30/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302569
Principal investigator 1 Incyte Corporation $189.90 10/22/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282369
Principal investigator 1 Incyte Corporation $86.56 10/22/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302565
Principal investigator 1 Incyte Corporation $18,096.00 10/22/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302567
Principal investigator 1 Incyte Corporation $1,339.00 10/08/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282371
Principal investigator 1 Incyte Corporation $981.40 10/08/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282373
Principal investigator 1 Incyte Corporation $3,750.00 10/08/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282379
Principal investigator 1 Incyte Corporation $2,333.00 10/08/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282381
Principal investigator 1 Incyte Corporation $2,333.00 10/08/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282383
Principal investigator 1 Incyte Corporation $2,333.00 10/08/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282385
Principal investigator 1 Incyte Corporation $2,333.00 10/08/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282387
Principal investigator 1 Incyte Corporation $22,995.12 10/07/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open Label (Part A) and a Double Blind, Randomized, Placebo Controlled (Part B) Study, With an Open Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata No dispute reported 06/30/2026 744304129
Principal investigator 1 Incyte Corporation $95.00 10/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292141
Principal investigator 1 Incyte Corporation $2,173.22 09/24/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282319
Principal investigator 1 Incyte Corporation $11,298.00 09/24/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282339
Principal investigator 1 Incyte Corporation $2,500.00 09/24/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282347
Principal investigator 1 Incyte Corporation $2,790.00 09/03/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302517
Principal investigator 1 Incyte Corporation $95.00 09/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292115
Principal investigator 1 Incyte Corporation $189.90 08/25/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282341
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302341
Principal investigator 1 Incyte Corporation $8.95 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302343
Principal investigator 1 Incyte Corporation $20.76 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302345
Principal investigator 1 Incyte Corporation $10.80 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302347
Principal investigator 1 Incyte Corporation $22.94 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302349
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302363
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302365
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302367
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302369
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302371
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302373
Principal investigator 1 Incyte Corporation $8.95 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302375
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302377
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302379
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302381
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302383
Principal investigator 1 Incyte Corporation $8.95 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302385
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302387
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302389
Principal investigator 1 Incyte Corporation $8.95 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302391
Principal investigator 1 Incyte Corporation $22.94 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302393
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302395
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302535
Principal investigator 1 Incyte Corporation $17.90 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302537
Principal investigator 1 Incyte Corporation $22.94 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302539
Principal investigator 1 Incyte Corporation $8.95 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302541
Principal investigator 1 Incyte Corporation $8.95 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302543
Principal investigator 1 Incyte Corporation $20.76 08/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302545
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,600.48 08/06/2020 Non-covered Recipient Entity
Duke University
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 736748637
Principal investigator 1 Incyte Corporation $95.00 08/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292097
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,360.19 07/29/2020 Covered Recipient Teaching Hospital
Duke University Hospital
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 736736217
Principal investigator 1 Incyte Corporation $211.00 07/21/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282343
Principal investigator 1 Incyte Corporation $168.80 07/21/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282351
Principal investigator 1 Incyte Corporation $95.00 07/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292093
Principal investigator 1 Incyte Corporation $2,837.30 06/23/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282309
Principal investigator 1 Incyte Corporation $211.00 06/23/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282311
Principal investigator 1 Incyte Corporation $5,301.90 06/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302483
Principal investigator 1 Incyte Corporation $1,759.90 06/02/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282303
Principal investigator 1 Incyte Corporation $2,230.00 06/02/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282305
Principal investigator 1 Incyte Corporation $1,393.00 06/02/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282307
Principal investigator 1 Incyte Corporation $95.00 06/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292091
Principal investigator 1 Incyte Corporation $1,227.00 05/29/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292079
Principal investigator 1 Incyte Corporation $3,019.50 05/26/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282301
Principal investigator 1 Incyte Corporation $4,141.00 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282287
Principal investigator 1 Incyte Corporation $2,358.00 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282289
Principal investigator 1 Incyte Corporation $2,230.00 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282291
Principal investigator 1 Incyte Corporation $1,862.00 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282293
Principal investigator 1 Incyte Corporation $211.00 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282295
Principal investigator 1 Incyte Corporation $2,518.00 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282297
Principal investigator 1 Incyte Corporation $2,343.00 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282299
Principal investigator 1 Incyte Corporation $211.00 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282313
Principal investigator 1 Incyte Corporation $4,141.00 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282315
Principal investigator 1 Incyte Corporation $3,847.60 05/14/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282317
Principal investigator 1 Incyte Corporation $8,918.10 05/12/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302463
Principal investigator 1 Incyte Corporation $25,960.00 05/12/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open Label (Part A) and a Double Blind, Randomized, Placebo Controlled (Part B) Study, With an Open Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata No dispute reported 06/30/2026 744304091
Principal investigator 1 Incyte Corporation $4,972.80 05/12/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open Label (Part A) and a Double Blind, Randomized, Placebo Controlled (Part B) Study, With an Open Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata No dispute reported 06/30/2026 744304093
Principal investigator 1 Incyte Corporation $750.00 05/12/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open Label (Part A) and a Double Blind, Randomized, Placebo Controlled (Part B) Study, With an Open Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata No dispute reported 06/30/2026 744304097
Principal investigator 1 Incyte Corporation $8.95 05/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302285
Principal investigator 1 Incyte Corporation $17.90 05/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302287
Principal investigator 1 Incyte Corporation $6.00 05/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302289
Principal investigator 1 Incyte Corporation $8.95 05/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302325
Principal investigator 1 Incyte Corporation $95.00 05/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292089
Principal investigator 1 Incyte Corporation $21,364.89 04/27/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open Label (Part A) and a Double Blind, Randomized, Placebo Controlled (Part B) Study, With an Open Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata No dispute reported 06/30/2026 744304075
Principal investigator 1 Incyte Corporation $43,399.80 04/23/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302459
Principal investigator 1 Genentech, Inc. $15,433.50 04/09/2020 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CAPECITABINE BEVACIZUMAB PLUS ATEZOLIZUMAB VERSUS CAPECITABINE BEVACIZUMAB PLUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 743075553
Principal investigator 1 Incyte Corporation $129.50 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302273
Principal investigator 1 Incyte Corporation $48.00 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302275
Principal investigator 1 Incyte Corporation $42.50 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302277
Principal investigator 1 Incyte Corporation $10.03 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302279
Principal investigator 1 Incyte Corporation $16.20 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302281
Principal investigator 1 Incyte Corporation $10.80 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302283
Principal investigator 1 Incyte Corporation $16.20 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302317
Principal investigator 1 Incyte Corporation $10.80 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302319
Principal investigator 1 Incyte Corporation $10.80 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302321
Principal investigator 1 Incyte Corporation $16.20 04/08/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302323
Principal investigator 1 Incyte Corporation $95.00 04/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292087
Principal investigator 1 Incyte Corporation $200.00 03/31/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302441
Principal investigator 1 Incyte Corporation $478.06 03/31/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302443
Principal investigator 1 Incyte Corporation $2,694.00 03/17/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282235
Principal investigator 1 Incyte Corporation $5,269.00 03/17/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282237
Principal investigator 1 Incyte Corporation $915.50 03/17/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282239
Principal investigator 1 Incyte Corporation $25,960.00 03/11/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open Label (Part A) and a Double Blind, Randomized, Placebo Controlled (Part B) Study, With an Open Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata No dispute reported 06/30/2026 744304037
Principal investigator 1 Incyte Corporation $4,972.80 03/11/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open Label (Part A) and a Double Blind, Randomized, Placebo Controlled (Part B) Study, With an Open Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata No dispute reported 06/30/2026 744304039
Principal investigator 1 Incyte Corporation $750.00 03/11/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open Label (Part A) and a Double Blind, Randomized, Placebo Controlled (Part B) Study, With an Open Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata No dispute reported 06/30/2026 744304041
Principal investigator 1 Incyte Corporation $8.95 03/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302249
Principal investigator 1 Incyte Corporation $22.51 03/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302251
Principal investigator 1 Incyte Corporation $8.95 03/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302265
Principal investigator 1 Incyte Corporation $8.95 03/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302267
Principal investigator 1 Incyte Corporation $8.95 03/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302269
Principal investigator 1 Incyte Corporation $8.95 03/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744302271
Principal investigator 1 Genentech, Inc. $72,438.55 03/06/2020 Non-covered Recipient Entity
MAYO CLINIC MAYO CLINIC COLLEGE OF MEDICINE
A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CAPECITABINE BEVACIZUMAB PLUS ATEZOLIZUMAB VERSUS CAPECITABINE BEVACIZUMAB PLUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 743075543
Principal investigator 1 Incyte Corporation $95.00 03/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292067
Principal investigator 1 Incyte Corporation $5,314.50 02/25/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282233
Principal investigator 1 Incyte Corporation $96,045.14 02/20/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers No dispute reported 06/30/2026 744304031
Principal investigator 1 Incyte Corporation $211.00 02/12/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282223
Principal investigator 1 Incyte Corporation $2,012.00 02/12/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282227
Principal investigator 1 Incyte Corporation $2,279.00 02/12/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282229
Principal investigator 1 Incyte Corporation $1,360.60 02/12/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282265
Principal investigator 1 Incyte Corporation $442.00 02/11/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292061
Principal investigator 1 Incyte Corporation $11,970.00 02/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302423
Principal investigator 1 Incyte Corporation $665.00 02/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302425
Principal investigator 1 Incyte Corporation $3,325.00 02/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302427
Principal investigator 1 Incyte Corporation $399.00 02/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302429
Principal investigator 1 Incyte Corporation $1,330.00 02/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302431
Principal investigator 1 Incyte Corporation $2,660.00 02/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302433
Principal investigator 1 Incyte Corporation $2,500.00 02/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302435
Principal investigator 1 Incyte Corporation $831.00 02/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302437
Principal investigator 1 Incyte Corporation $2,500.00 02/11/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302445
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,238.00 02/10/2020 Non-covered Recipient Entity
Duke Comp Cancer Cnt
Phase IIB TMB High Pan Tumor FA for tTMB No dispute reported 06/30/2026 736759693
Principal investigator 1 Incyte Corporation $5.40 02/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302243
Principal investigator 1 Incyte Corporation $10.03 02/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302245
Principal investigator 1 Incyte Corporation $17.90 02/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302247
Principal investigator 1 Incyte Corporation $5.40 02/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302261
Principal investigator 1 Incyte Corporation $5.40 02/10/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302263
Principal investigator 1 AstraZeneca Pharmaceuticals LP $731.52 02/06/2020 Non-covered Recipient Entity
Duke Clinical Research Inst
A Phase 1b/2, Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma No dispute reported 06/30/2026 736742999
Principal investigator 1 Incyte Corporation $95.00 02/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292065
Principal investigator 1 Incyte Corporation $211.00 01/28/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282225
Principal investigator 1 Incyte Corporation $2,641.80 01/28/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282231
Principal investigator 1 Incyte Corporation $211.00 01/28/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282263
Principal investigator 1 Incyte Corporation $3,355.00 01/28/2020 Non-covered Recipient Entity
DUKE UNIVERSITY
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744282267
Principal investigator 1 Incyte Corporation $26.06 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302227
Principal investigator 1 Incyte Corporation $5.40 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302229
Principal investigator 1 Incyte Corporation $8.95 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302231
Principal investigator 1 Incyte Corporation $10.03 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302233
Principal investigator 1 Incyte Corporation $20.06 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302235
Principal investigator 1 Incyte Corporation $64.75 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302237
Principal investigator 1 Incyte Corporation $27.00 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302239
Principal investigator 1 Incyte Corporation $44.75 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302241
Principal investigator 1 Incyte Corporation $5.40 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302253
Principal investigator 1 Incyte Corporation $5.40 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302255
Principal investigator 1 Incyte Corporation $27.00 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302257
Principal investigator 1 Incyte Corporation $27.00 01/09/2020 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744302259
Principal investigator 1 Incyte Corporation $96,045.14 01/09/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers No dispute reported 06/30/2026 744304025
Principal investigator 1 Incyte Corporation $95.00 01/01/2020 Non-covered Recipient Entity
DUKE UNIVERSITY MEDICAL CENTER
An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of a Single 10mg Dose of INCB028050 Compared to Normal Healthy Adult Volunteers No dispute reported 06/30/2026 744292063